董事介绍
注:董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Linda Maxwell | 女 | Director | 52 | 未披露 | 未持股 | 2026-01-21 |
| Jan Malcolm | 女 | Director | -- | 未披露 | 未持股 | 2026-01-21 |
| Nilda Mesa | 女 | Director | -- | 未披露 | 未持股 | 2026-01-21 |
| Martine Rothblatt | 女 | Chairperson, Chief Executive Officer and Director | -- | 未披露 | 未持股 | 2026-01-21 |
| Kevin J. Tracey | 男 | Director | -- | 未披露 | 未持股 | 2026-01-21 |
| Raymond Dwek | 男 | Director | 84 | 48.87万美元 | 未持股 | 2026-01-21 |
| Christopher Patusky | 男 | Director | 62 | 57.10万美元 | 未持股 | 2026-01-21 |
| Tommy Thompson | 男 | Director | 84 | 49.60万美元 | 未持股 | 2026-01-21 |
| Louis Sullivan | 男 | Director | 91 | 51.10万美元 | 未持股 | 2026-01-21 |
| Ray Kurzweil | 男 | Director | 78 | 48.10万美元 | 未持股 | 2026-01-21 |
| Christopher Causey | 男 | Director | 63 | 52.10万美元 | 未持股 | 2026-01-21 |
| Richard Giltner | 男 | Director | 62 | 52.87万美元 | 未持股 | 2026-01-21 |
| Martine A. Rothblatt | 女 | Chairperson, Chief Executive Officer and Director | 71 | 3713.32万美元 | 未持股 | 2026-01-21 |
| Judy D. Olian | 女 | Director | 74 | 50.37万美元 | 未持股 | 2026-01-21 |
高管介绍
注:高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James C. Edgemond | 男 | Chief Financial Officer and Treasurer | 58 | 865.30万美元 | 未持股 | 2026-01-21 |
| Michael Benkowitz | 男 | President and Chief Operating Officer | 54 | 1155.75万美元 | 未持股 | 2026-01-21 |
| Paul A. Mahon | 男 | Executive Vice President, General Counsel and Corporate Secretary | 62 | 1287.14万美元 | 未持股 | 2026-01-21 |
| Martine A. Rothblatt | 女 | Chairperson, Chief Executive Officer and Director | 71 | 3713.32万美元 | 未持股 | 2026-01-21 |
董事简历
中英对照 |  中文 |  英文- Linda Maxwell
-
Linda Maxwell,自2005年起担任外科医生;自2015年6月起担任Ryerson大学生物医学区执行主任;牛津大学技术转让经理(2013年6月至2014年7月)。
Linda Maxwell,Surgeon since 2005; Executive Director of Biomedical Zone Ryerson University since June 2015; Technology Transfer Manager at University of Oxford (June 2013 to July 2014). - Linda Maxwell,自2005年起担任外科医生;自2015年6月起担任Ryerson大学生物医学区执行主任;牛津大学技术转让经理(2013年6月至2014年7月)。
- Linda Maxwell,Surgeon since 2005; Executive Director of Biomedical Zone Ryerson University since June 2015; Technology Transfer Manager at University of Oxford (June 2013 to July 2014).
- Jan Malcolm
-
扬·马尔科姆(Jan Malcolm)是一位在卫生政策、公共卫生、医疗保健融资和交付方面卓有成就的领导者。她展现了在整个职业生涯中致力于改善公众健康和复杂人群的护理。马尔科姆曾两次在代表两个政党的三名州长领导下担任明尼苏达州卫生专员(从1999年至2003年,从2018年到2023年1月退休),作为首批强调健康差异和健康的社会决定因素影响的医疗保健领导人之一,她赢得了全国声誉。在新冠疫情期间,作为卫生专员,她还在教育公众、创建与明尼苏达州人民共享新冠肺炎数据的动态且对United Therapeutics Corporation友好的系统以及迅速扩大检测能力方面发挥了重要和可见的作用。在新冠疫情之前,明尼苏达州卫生部每年从所有资金来源获得的预算超过6亿美元,并雇用了1500多名高度专业化的工作人员。在大流行期间,由于联邦资金、工作人员重新部署和临时承包商,预算和人员配置增加了一倍多。为表彰她的诸多成就,2024年2月,美国医学协会(AMA)向马尔科姆女士颁发了AMA杰出政府服务奖。在2018年被重新任命为专员之前,马尔科姆女士是明尼苏达大学公共卫生学院的兼职教员,在那里她共同指导了由罗伯特·伍德·约翰逊基金会资助的国家研究和领导力发展计划。马尔科姆女士还曾于1994年至1999年和2013年至2016年担任Allina卫生系统副总裁,职责涵盖企业传播、公共事务、政府关系、卫生政策、社区关系和慈善事业。从2005年到2013年,她担任勇气中心的首席执行官,该中心是一家领先的残疾人康复和健康服务提供商,每年为超过12,000名患者提供服务。马尔科姆女士获得达特茅斯学院哲学和心理学学士学位。
Jan Malcolm,is an accomplished leader in health policy, public health, and health care finance and delivery. She has demonstrated a career-long dedication to improving the health of the public and the care of complex populations. Twice Minnesota's Commissioner of Health under three governors representing two political parties (from 1999-2003 and from 2018 until her retirement in January 2023), Ms. Malcolm earned a national reputation as one of the first health care leaders to highlight health disparities and the impact of social determinants of health. As Health Commissioner during the COVID-19 pandemic, she also played an instrumental and visible role in educating the public, creating dynamic and United Therapeutics Corporation er-friendly systems for sharing COVID-19 data with the people of Minnesota, and rapidly expanding testing capacity. Prior to the COVID-19 pandemic, the Minnesota Department of Health had a budget of over $600 million per year from all funding sources, and employed over 1,500 highly professional staff. During the pandemic the budget and staffing more than doubled with federal funds, staff re-deployments, and temporary contractors. In recognition of her many accomplishments, in February 2024 the American Medical Association (AMA) presented Ms. Malcolm with the AMA Award for Outstanding Government Service.Prior to being re-appointed Commissioner in 2018, Ms. Malcolm was an adjunct faculty member at the University of Minnesota School of Public Health, where she co-directed a national research and leadership development program funded by the Robert Wood Johnson Foundation. Ms. Malcolm also served as vice president of the Allina Health system from 1994 to 1999 and 2013 to 2016, with responsibilities spanning corporate communications, public affairs, government relations, health policy, community relations, and philanthropy. From 2005 to 2013, she served as CEO of the Courage Center, a leading provider of rehabilitation and health services for people with disabilities serving over 12,000 patients annually. Ms. Malcolm received a bachelor's degree in philosophy and psychology from Dartmouth College. - 扬·马尔科姆(Jan Malcolm)是一位在卫生政策、公共卫生、医疗保健融资和交付方面卓有成就的领导者。她展现了在整个职业生涯中致力于改善公众健康和复杂人群的护理。马尔科姆曾两次在代表两个政党的三名州长领导下担任明尼苏达州卫生专员(从1999年至2003年,从2018年到2023年1月退休),作为首批强调健康差异和健康的社会决定因素影响的医疗保健领导人之一,她赢得了全国声誉。在新冠疫情期间,作为卫生专员,她还在教育公众、创建与明尼苏达州人民共享新冠肺炎数据的动态且对United Therapeutics Corporation友好的系统以及迅速扩大检测能力方面发挥了重要和可见的作用。在新冠疫情之前,明尼苏达州卫生部每年从所有资金来源获得的预算超过6亿美元,并雇用了1500多名高度专业化的工作人员。在大流行期间,由于联邦资金、工作人员重新部署和临时承包商,预算和人员配置增加了一倍多。为表彰她的诸多成就,2024年2月,美国医学协会(AMA)向马尔科姆女士颁发了AMA杰出政府服务奖。在2018年被重新任命为专员之前,马尔科姆女士是明尼苏达大学公共卫生学院的兼职教员,在那里她共同指导了由罗伯特·伍德·约翰逊基金会资助的国家研究和领导力发展计划。马尔科姆女士还曾于1994年至1999年和2013年至2016年担任Allina卫生系统副总裁,职责涵盖企业传播、公共事务、政府关系、卫生政策、社区关系和慈善事业。从2005年到2013年,她担任勇气中心的首席执行官,该中心是一家领先的残疾人康复和健康服务提供商,每年为超过12,000名患者提供服务。马尔科姆女士获得达特茅斯学院哲学和心理学学士学位。
- Jan Malcolm,is an accomplished leader in health policy, public health, and health care finance and delivery. She has demonstrated a career-long dedication to improving the health of the public and the care of complex populations. Twice Minnesota's Commissioner of Health under three governors representing two political parties (from 1999-2003 and from 2018 until her retirement in January 2023), Ms. Malcolm earned a national reputation as one of the first health care leaders to highlight health disparities and the impact of social determinants of health. As Health Commissioner during the COVID-19 pandemic, she also played an instrumental and visible role in educating the public, creating dynamic and United Therapeutics Corporation er-friendly systems for sharing COVID-19 data with the people of Minnesota, and rapidly expanding testing capacity. Prior to the COVID-19 pandemic, the Minnesota Department of Health had a budget of over $600 million per year from all funding sources, and employed over 1,500 highly professional staff. During the pandemic the budget and staffing more than doubled with federal funds, staff re-deployments, and temporary contractors. In recognition of her many accomplishments, in February 2024 the American Medical Association (AMA) presented Ms. Malcolm with the AMA Award for Outstanding Government Service.Prior to being re-appointed Commissioner in 2018, Ms. Malcolm was an adjunct faculty member at the University of Minnesota School of Public Health, where she co-directed a national research and leadership development program funded by the Robert Wood Johnson Foundation. Ms. Malcolm also served as vice president of the Allina Health system from 1994 to 1999 and 2013 to 2016, with responsibilities spanning corporate communications, public affairs, government relations, health policy, community relations, and philanthropy. From 2005 to 2013, she served as CEO of the Courage Center, a leading provider of rehabilitation and health services for people with disabilities serving over 12,000 patients annually. Ms. Malcolm received a bachelor's degree in philosophy and psychology from Dartmouth College.
- Nilda Mesa
-
Nilda Mesa在城市、州、国家和全球各级的环境、能源和可持续发展方面拥有长期和创新的职业生涯,现在撰写并广泛介绍与其相关的气候、能源、公平和城市系统。从2014年到2016年,梅萨教授担任纽约市市长可持续发展办公室主任,在那里她领导了该市开创性的OneNYC长期可持续发展计划。作为纽约市的首席可持续发展官,她负责监督气候、能源、可持续性、空气质量和公共卫生、废物、绿色建筑、交通、公共教育和其他举措方面的项目。2016年,她回到此前曾任职的哥伦比亚大学,担任国际和公共事务学院兼职教授,并担任地球研究所哥伦比亚可持续城市发展中心城市可持续性和公平规划项目主任。她还是建筑、规划、保护研究生院的兼职教授。2006年,她创立了哥伦比亚环境管理办公室,这是美国首批大学之一。2012年至2014年,她还担任哥伦比亚新闻学院的首席行政官。在加入哥伦比亚大学之前,梅萨教授曾在白宫环境质量委员会、美国空军、美国环境保护署和加州总检察长办公室担任环境领导职务,并在公共和私营部门执业。她的工作涉及广泛的国际经验,包括最近于2018年至2021年被任命为法国国际研究型大学SciencesPO(巴黎政治研究所)巴黎国际事务学院的客座教授和讲师。她是《协作促进气候复原力》(Routledge,2021年)一书的合著者,也是《更智慧的纽约市:城市机构如何创新》(哥伦比亚大学出版社,2019年)的撰稿人。她毕业于哈佛法学院和西北大学。
Nilda Mesa,has had a long and innovative career in environment, energy, and sustainability at the city, state, national, and global levels, and now writes and presents extensively on climate, energy, equity, and urban systems relating to them. From 2014 to 2016, Professor Mesa served as Director of the New York City Mayor's Office of Sustainability, where she led the pathbreaking OneNYC long-term sustainability plan for the city. As chief sustainability officer for New York City, she oversaw programs in climate, energy, sustainability, air quality and public health, waste, green buildings, transportation, public education, and other initiatives. In 2016, she returned to Columbia University, where she had previously served, as an adjunct professor at the School of International and Public Affairs, as well as Director of the Urban Sustainability and Equity Planning Program with Columbia's Center for Sustainable Urban Development at the Earth Institute. She was also Adjunct Professor in the Graduate School of Architecture, Planning, and Preservation. In 2006, she founded Columbia's Office of Environmental Stewardship, one of the first in the United States for a university. She also served as Chief Administrative Officer at the Columbia Journalism School from 2012 to 2014. Before joining Columbia, Professor Mesa served in environmental leadership roles at the White House Council on Environmental Quality, the U.S. Air Force, the U.S. Environmental Protection Agency, and the California Attorney General's office, and practiced law in both the public and private sectors. Her work has involved extensive international experience, including most recently a 2018 to 2021 appointment as a visiting professor and lecturer at the Paris School of International Affairs at SciencesPo (Paris Institute of Political Studies), an international research university in France. She is the co-author of Collaborating for Climate Resilience (Routledge, 2021), and a contributor to Smarter New York City: How City Agencies Innovate (Columbia University Press, 2019). She is a graduate of Harvard Law School and Northwestern University. - Nilda Mesa在城市、州、国家和全球各级的环境、能源和可持续发展方面拥有长期和创新的职业生涯,现在撰写并广泛介绍与其相关的气候、能源、公平和城市系统。从2014年到2016年,梅萨教授担任纽约市市长可持续发展办公室主任,在那里她领导了该市开创性的OneNYC长期可持续发展计划。作为纽约市的首席可持续发展官,她负责监督气候、能源、可持续性、空气质量和公共卫生、废物、绿色建筑、交通、公共教育和其他举措方面的项目。2016年,她回到此前曾任职的哥伦比亚大学,担任国际和公共事务学院兼职教授,并担任地球研究所哥伦比亚可持续城市发展中心城市可持续性和公平规划项目主任。她还是建筑、规划、保护研究生院的兼职教授。2006年,她创立了哥伦比亚环境管理办公室,这是美国首批大学之一。2012年至2014年,她还担任哥伦比亚新闻学院的首席行政官。在加入哥伦比亚大学之前,梅萨教授曾在白宫环境质量委员会、美国空军、美国环境保护署和加州总检察长办公室担任环境领导职务,并在公共和私营部门执业。她的工作涉及广泛的国际经验,包括最近于2018年至2021年被任命为法国国际研究型大学SciencesPO(巴黎政治研究所)巴黎国际事务学院的客座教授和讲师。她是《协作促进气候复原力》(Routledge,2021年)一书的合著者,也是《更智慧的纽约市:城市机构如何创新》(哥伦比亚大学出版社,2019年)的撰稿人。她毕业于哈佛法学院和西北大学。
- Nilda Mesa,has had a long and innovative career in environment, energy, and sustainability at the city, state, national, and global levels, and now writes and presents extensively on climate, energy, equity, and urban systems relating to them. From 2014 to 2016, Professor Mesa served as Director of the New York City Mayor's Office of Sustainability, where she led the pathbreaking OneNYC long-term sustainability plan for the city. As chief sustainability officer for New York City, she oversaw programs in climate, energy, sustainability, air quality and public health, waste, green buildings, transportation, public education, and other initiatives. In 2016, she returned to Columbia University, where she had previously served, as an adjunct professor at the School of International and Public Affairs, as well as Director of the Urban Sustainability and Equity Planning Program with Columbia's Center for Sustainable Urban Development at the Earth Institute. She was also Adjunct Professor in the Graduate School of Architecture, Planning, and Preservation. In 2006, she founded Columbia's Office of Environmental Stewardship, one of the first in the United States for a university. She also served as Chief Administrative Officer at the Columbia Journalism School from 2012 to 2014. Before joining Columbia, Professor Mesa served in environmental leadership roles at the White House Council on Environmental Quality, the U.S. Air Force, the U.S. Environmental Protection Agency, and the California Attorney General's office, and practiced law in both the public and private sectors. Her work has involved extensive international experience, including most recently a 2018 to 2021 appointment as a visiting professor and lecturer at the Paris School of International Affairs at SciencesPo (Paris Institute of Political Studies), an international research university in France. She is the co-author of Collaborating for Climate Resilience (Routledge, 2021), and a contributor to Smarter New York City: How City Agencies Innovate (Columbia University Press, 2019). She is a graduate of Harvard Law School and Northwestern University.
- Martine Rothblatt
-
Martine Rothblatt,1996年创立联合治疗,自成立以来一直担任董事长兼首席执行官。此前,她创建了卫星广播公司SiriusXM。她是十项美国专利的共同发明人,还有更多专利正在申请中。她的开创性著作《你的生活或我的:地球伦理学如何解决异种移植中私人和公共利益之间的冲突》,预计需要全球病毒生物监测和大幅扩大可移植器官的供应。Rothblatt博士还在她2014年出版的《Virtually Human》一书中分析了类人网络能力的社会伦理问题,就像从大型语言模型中出现的那样。
Martine Rothblatt,founded United Therapeutics in 1996 and has served as Chairperson and Chief Executive Officer since its inception. Previously, she created the satellite radio company SiriusXM. She is a co-inventor on ten U.S. patents, with additional patents pending. Her pioneering book, Your Life or Mine: How Geoethics Can Resolve the Conflict Between Private and Public Interests in Xenotransplantation, anticipated the need both for global virus bio-surveillance and a greatly expanded supply of transplantable organs. Dr. Rothblatt has also analyzed the socio-ethical issues of human-like cyber competencies, as are emerging from large language models, in her 2014 book Virtually Human. - Martine Rothblatt,1996年创立联合治疗,自成立以来一直担任董事长兼首席执行官。此前,她创建了卫星广播公司SiriusXM。她是十项美国专利的共同发明人,还有更多专利正在申请中。她的开创性著作《你的生活或我的:地球伦理学如何解决异种移植中私人和公共利益之间的冲突》,预计需要全球病毒生物监测和大幅扩大可移植器官的供应。Rothblatt博士还在她2014年出版的《Virtually Human》一书中分析了类人网络能力的社会伦理问题,就像从大型语言模型中出现的那样。
- Martine Rothblatt,founded United Therapeutics in 1996 and has served as Chairperson and Chief Executive Officer since its inception. Previously, she created the satellite radio company SiriusXM. She is a co-inventor on ten U.S. patents, with additional patents pending. Her pioneering book, Your Life or Mine: How Geoethics Can Resolve the Conflict Between Private and Public Interests in Xenotransplantation, anticipated the need both for global virus bio-surveillance and a greatly expanded supply of transplantable organs. Dr. Rothblatt has also analyzed the socio-ethical issues of human-like cyber competencies, as are emerging from large language models, in her 2014 book Virtually Human.
- Kevin J. Tracey
-
Kevin J. Tracey是范斯坦医学研究所的总裁、首席执行官和Karches家族医学研究杰出主席。他是Hofstra/Northwell的Donald and Barbara Zucker医学院的分子医学和神经外科教授,也是Northwell Health的研究执行副总裁。作为炎症和生物电子医学科学领域的领导者,Tracey博士的贡献包括发现和分子绘制控制免疫的神经回路,以及鉴定单克隆抗TNF抗体的治疗作用。Tracey博士是多家生物技术公司的联合创始人,其中包括生物电子医学的行业领导者SetPoint Medical。
Kevin J. Tracey,is President, CEO, and the Karches Family Distinguished Chair in Medical Research at The Feinstein Institutes for Medical Research. He is a Professor of Molecular Medicine and Neurosurgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Executive Vice President, Research, at Northwell Health. A leader in the scientific fields of inflammation and bioelectronic medicine, Dr. Tracey's contributions include discovery and molecular mapping of neural circuits controlling immunity, as well as identifying the therapeutic action of monoclonal anti-TNF antibodies. Dr. Tracey is the co-founder of several biotechnology companies, including SetPoint Medical, the industry leader in bioelectronic medicine. - Kevin J. Tracey是范斯坦医学研究所的总裁、首席执行官和Karches家族医学研究杰出主席。他是Hofstra/Northwell的Donald and Barbara Zucker医学院的分子医学和神经外科教授,也是Northwell Health的研究执行副总裁。作为炎症和生物电子医学科学领域的领导者,Tracey博士的贡献包括发现和分子绘制控制免疫的神经回路,以及鉴定单克隆抗TNF抗体的治疗作用。Tracey博士是多家生物技术公司的联合创始人,其中包括生物电子医学的行业领导者SetPoint Medical。
- Kevin J. Tracey,is President, CEO, and the Karches Family Distinguished Chair in Medical Research at The Feinstein Institutes for Medical Research. He is a Professor of Molecular Medicine and Neurosurgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Executive Vice President, Research, at Northwell Health. A leader in the scientific fields of inflammation and bioelectronic medicine, Dr. Tracey's contributions include discovery and molecular mapping of neural circuits controlling immunity, as well as identifying the therapeutic action of monoclonal anti-TNF antibodies. Dr. Tracey is the co-founder of several biotechnology companies, including SetPoint Medical, the industry leader in bioelectronic medicine.
- Raymond Dwek
-
Raymond Dwek ,他是英国皇家学会(The Royal Society)(位于伦敦)的成员,也曾担任Glycobiology Institute的董事,以及the University of Oxford的糖生物学教授(1988年以来)。他曾担任 the Institute of Biology(一个专业的组织)的总裁(从2008年到2010年)。从2000年到2006年,他曾担任the university of oxford (牛津大学)的生物化学部门的负责人。Professor Dwek,他曾一直担任the university of oxford (牛津大学)的多种职务(1966年以来)。他于1988年担任Oxford GlycoSciences公司(在伦敦证券交易所和纳斯达克上市)的科学创始人,也曾担任董事会成员(直到2003年公司出售)。他是美国国会图书馆(the U.S. Library of Congress)的2007年科技和社会主席(Kluge Chair of Technology and Society)。他是糖生物学的创始人,研究糖链连接到蛋白质的结构、生物合成和生物。自2002年以来,他担任United Therapeutics公司的董事。
Raymond Dwek,is a Fellow of the Royal Society, London, and served as Director of the Glycobiology Institute at the University of Oxford from 1988 to 2021. He also served as Professor of Glycobiology at the University of Oxford from 1988 through 2009, and currently serves as Professor Emeritus. He was President of the Institute of Biology (a professional organization) from 2008 through 2010. From 2000 to 2006, Professor Dwek served as head of the Department of Biochemistry at the University of Oxford. Professor Dwek has been serving in various positions at the University of Oxford since 1966. In 1988, Professor Dwek was the scientific founder of Oxford GlycoSciences PLC, which was publicly traded on the London Stock Exchange and Nasdaq, and he served as a member of its board of directors until its sale in 2003. The company, in collaboration with Professor Dwek's Glycobiology Institute, successfully developed an FDA-approved treatment for Gaucher disease. He was the 2007 Kluge Chair of Technology and Society at the U.S. Library of Congress. Professor Dwek is the founder of glycobiology, the study of the structure, biosynthesis, and biology of sugar chains attached to proteins. Professor Dwek studied Chemistry at Manchester University. After completing his M.Sc., he pursued a DPhil in Chemistry. He holds a D.Sc and M.A from Oxford University. He has been elected Fellow of the Royal Society (FRS), Fellow of the Royal Society of Chemistry (FRSC), and an Honorary Fellow Royal Institute of Physicians (Hon FRCP), and was awarded the Commander of the Order of the British Empire (CBE) honour, as well as the Romanian Order of Merit. He has been awarded honorary degrees from numerous universities worldwide. - Raymond Dwek ,他是英国皇家学会(The Royal Society)(位于伦敦)的成员,也曾担任Glycobiology Institute的董事,以及the University of Oxford的糖生物学教授(1988年以来)。他曾担任 the Institute of Biology(一个专业的组织)的总裁(从2008年到2010年)。从2000年到2006年,他曾担任the university of oxford (牛津大学)的生物化学部门的负责人。Professor Dwek,他曾一直担任the university of oxford (牛津大学)的多种职务(1966年以来)。他于1988年担任Oxford GlycoSciences公司(在伦敦证券交易所和纳斯达克上市)的科学创始人,也曾担任董事会成员(直到2003年公司出售)。他是美国国会图书馆(the U.S. Library of Congress)的2007年科技和社会主席(Kluge Chair of Technology and Society)。他是糖生物学的创始人,研究糖链连接到蛋白质的结构、生物合成和生物。自2002年以来,他担任United Therapeutics公司的董事。
- Raymond Dwek,is a Fellow of the Royal Society, London, and served as Director of the Glycobiology Institute at the University of Oxford from 1988 to 2021. He also served as Professor of Glycobiology at the University of Oxford from 1988 through 2009, and currently serves as Professor Emeritus. He was President of the Institute of Biology (a professional organization) from 2008 through 2010. From 2000 to 2006, Professor Dwek served as head of the Department of Biochemistry at the University of Oxford. Professor Dwek has been serving in various positions at the University of Oxford since 1966. In 1988, Professor Dwek was the scientific founder of Oxford GlycoSciences PLC, which was publicly traded on the London Stock Exchange and Nasdaq, and he served as a member of its board of directors until its sale in 2003. The company, in collaboration with Professor Dwek's Glycobiology Institute, successfully developed an FDA-approved treatment for Gaucher disease. He was the 2007 Kluge Chair of Technology and Society at the U.S. Library of Congress. Professor Dwek is the founder of glycobiology, the study of the structure, biosynthesis, and biology of sugar chains attached to proteins. Professor Dwek studied Chemistry at Manchester University. After completing his M.Sc., he pursued a DPhil in Chemistry. He holds a D.Sc and M.A from Oxford University. He has been elected Fellow of the Royal Society (FRS), Fellow of the Royal Society of Chemistry (FRSC), and an Honorary Fellow Royal Institute of Physicians (Hon FRCP), and was awarded the Commander of the Order of the British Empire (CBE) honour, as well as the Romanian Order of Merit. He has been awarded honorary degrees from numerous universities worldwide.
- Christopher Patusky
-
Christopher Patusky,2012年以来,他曾一直担任Patusky Associates公司(为政府和私营部门客户提供战略建议)的创始负责人。2014年1月以来,他也曾担任Slater Run Vineyards公司(一个家庭农业葡萄园和酿酒厂)的执行经理。从2007年到2011年,他曾担任the Maryland Department of Transportation的董事和房地产职员,在那里他负责监督美国的房地产全州范围内的问题,包括它的理念下发展项目。他继续向the Maryland Department of Transportation提供兼职服务(2013年6月)。从2002年到2007年,他曾担任宾夕法尼亚大学费尔斯政府研究所(the Fels Institute of Government at the University of Pennsylvania)的教师,以及执行董事。从1989年到2000年,他从事法律事务,专注于诉讼、知识产权法律和商业公司。我们的董事会已经确定,他满足纳斯达克上市的金融复杂性要求标准。自2002年以来,他担任United Therapeutics公司的董事。
Christopher Patusky,has 35 years of experience in the private, public, and non-profit sectors. After graduating from Harvard Law School, he practiced law from 1988 to 2000, focusing on litigation, intellectual property, and business startups. His legal work included co-leading a team that obtained the first approval from the Federal Communications Commission and the United Nations' International Telecommunications Union of the United Therapeutics Corporation e of stratospheric stations for delivery of telecommunication services worldwide. After receiving a master's degree in governmental administration from the University of Pennsylvania in 2001, Mr. Patusky served from 2002 to 2007 as Executive Director and faculty member at the University of Pennsylvania's Fels Institute of Government where he directed the implementation of an innovative performance management system for the 270 schools of the Philadelphia School District, which was recognized by the IBM Business of Government awards program. From 2007 to 2011, Mr. Patusky was the Real Estate Director for the Maryland Department of Transportation with oversight responsibility for real estate policy for all modes of transportation, service on the department's sustainability committee and implementation of the Governor's Transit Oriented Development (TOD) program, including the drafting and passage of Maryland's first of kind TOD law. Since 2012, Mr. Patusky has served as the founding principal of Patusky Associates, LLC, which serves as a personal investment vehicle, and as an executive manager of Slater Run Vineyards, LLC, his family's farm-based vineyard and winery. Mr. Patusky received a bachelor of science in history and political science from Northwestern University. - Christopher Patusky,2012年以来,他曾一直担任Patusky Associates公司(为政府和私营部门客户提供战略建议)的创始负责人。2014年1月以来,他也曾担任Slater Run Vineyards公司(一个家庭农业葡萄园和酿酒厂)的执行经理。从2007年到2011年,他曾担任the Maryland Department of Transportation的董事和房地产职员,在那里他负责监督美国的房地产全州范围内的问题,包括它的理念下发展项目。他继续向the Maryland Department of Transportation提供兼职服务(2013年6月)。从2002年到2007年,他曾担任宾夕法尼亚大学费尔斯政府研究所(the Fels Institute of Government at the University of Pennsylvania)的教师,以及执行董事。从1989年到2000年,他从事法律事务,专注于诉讼、知识产权法律和商业公司。我们的董事会已经确定,他满足纳斯达克上市的金融复杂性要求标准。自2002年以来,他担任United Therapeutics公司的董事。
- Christopher Patusky,has 35 years of experience in the private, public, and non-profit sectors. After graduating from Harvard Law School, he practiced law from 1988 to 2000, focusing on litigation, intellectual property, and business startups. His legal work included co-leading a team that obtained the first approval from the Federal Communications Commission and the United Nations' International Telecommunications Union of the United Therapeutics Corporation e of stratospheric stations for delivery of telecommunication services worldwide. After receiving a master's degree in governmental administration from the University of Pennsylvania in 2001, Mr. Patusky served from 2002 to 2007 as Executive Director and faculty member at the University of Pennsylvania's Fels Institute of Government where he directed the implementation of an innovative performance management system for the 270 schools of the Philadelphia School District, which was recognized by the IBM Business of Government awards program. From 2007 to 2011, Mr. Patusky was the Real Estate Director for the Maryland Department of Transportation with oversight responsibility for real estate policy for all modes of transportation, service on the department's sustainability committee and implementation of the Governor's Transit Oriented Development (TOD) program, including the drafting and passage of Maryland's first of kind TOD law. Since 2012, Mr. Patusky has served as the founding principal of Patusky Associates, LLC, which serves as a personal investment vehicle, and as an executive manager of Slater Run Vineyards, LLC, his family's farm-based vineyard and winery. Mr. Patusky received a bachelor of science in history and political science from Northwestern University.
- Tommy Thompson
-
Tommy Thompson,2005年进入私营部门之前,他在公共服务获得了漫长而卓越职业生涯。他曾担任 the U.S. Department of Health and Human Services的秘书(从2001年到2005年),也曾主张所有美国人的健康和福利。他也曾担任四任威斯康辛州州长(从1987年到2001年)。Governor Thompson,他曾担任Akin Gump Strauss Hauer & Feld公司的律师事务所(位于华盛顿特区)的合伙人(从2005年到2012年1月他为了竞选美国参议院辞职)。从2005年到2009年,他还担任the Deloitte Center for Health Solutions的独立主席,负责研发解决一些我们国家最紧迫的卫生保健和公共卫生相关的挑战。他也曾担任AGA Medical Holdings公司的董事会主席(从2005年到2010年),也是Centene Corporation、C.R.Bard公司、Cytori Therapeutics公司、Physicians Realty Trust 公司和TherapeuticsMD公司的董事会成员。他此前曾任职许多其它上市公司的董事会,百科Cancer Genetics公司、CareView Communications公司、CNS Response公司、SpectraScience公司、 X Shares Advisors公司。我们的董事会已经确定,他满足纳斯达克上市的金融复杂性要求标准。自2010年以来,他担任United Therapeutics公司的董事。
Tommy Thompson,enjoyed a long and distinguished career in public service. As Secretary of the U.S. Department of Health and Human Services from 2001 to 2005, he was a leading advocate for the health and welfare of all Americans. He also served four terms as Governor of Wisconsin from 1987 to 2001. Governor Thompson served as Interim President of the University of Wisconsin System from July 2020 through March 2022. Governor Thompson served as a partner at the law firm of Akin Gump Strauss Hauer & Feld LLP in Washington, D.C. from 2005 until January 2012, and as an Adjunct Senior Advisor from 2017 to 2020. From 2005 to 2009, he also served as the Independent Chair of the Deloitte Center for Health Solutions, which researches and develops solutions to some of United Therapeutics Corporation nation's most pressing health care and public health related challenges. He currently serves on the boards of directors of Healthpeak Properties, Inc. and TherapeuticsMD, Inc., each of which is publicly-traded. He resigned as executive chair of the TherapeuticsMD board in March 2024, and was re-appointed as the non-executive chair of the TherapeuticsMD board. He previously served on the boards of various other public companies, including AGA Medical Holdings, Inc., Cancer Genetics Inc., CareView Communications, Inc., Centene Corporation, CNS Response, Inc., C.R. Bard, Inc., Cytori Therapeutics, Inc., Scilex Holding Company, Physicians Realty Trust, SpectraScience, Tyme Technologies, Inc., and X Shares Advisors. Governor Thompson earned his bachelor and juris doctor degrees from the University of Wisconsin–Madison. - Tommy Thompson,2005年进入私营部门之前,他在公共服务获得了漫长而卓越职业生涯。他曾担任 the U.S. Department of Health and Human Services的秘书(从2001年到2005年),也曾主张所有美国人的健康和福利。他也曾担任四任威斯康辛州州长(从1987年到2001年)。Governor Thompson,他曾担任Akin Gump Strauss Hauer & Feld公司的律师事务所(位于华盛顿特区)的合伙人(从2005年到2012年1月他为了竞选美国参议院辞职)。从2005年到2009年,他还担任the Deloitte Center for Health Solutions的独立主席,负责研发解决一些我们国家最紧迫的卫生保健和公共卫生相关的挑战。他也曾担任AGA Medical Holdings公司的董事会主席(从2005年到2010年),也是Centene Corporation、C.R.Bard公司、Cytori Therapeutics公司、Physicians Realty Trust 公司和TherapeuticsMD公司的董事会成员。他此前曾任职许多其它上市公司的董事会,百科Cancer Genetics公司、CareView Communications公司、CNS Response公司、SpectraScience公司、 X Shares Advisors公司。我们的董事会已经确定,他满足纳斯达克上市的金融复杂性要求标准。自2010年以来,他担任United Therapeutics公司的董事。
- Tommy Thompson,enjoyed a long and distinguished career in public service. As Secretary of the U.S. Department of Health and Human Services from 2001 to 2005, he was a leading advocate for the health and welfare of all Americans. He also served four terms as Governor of Wisconsin from 1987 to 2001. Governor Thompson served as Interim President of the University of Wisconsin System from July 2020 through March 2022. Governor Thompson served as a partner at the law firm of Akin Gump Strauss Hauer & Feld LLP in Washington, D.C. from 2005 until January 2012, and as an Adjunct Senior Advisor from 2017 to 2020. From 2005 to 2009, he also served as the Independent Chair of the Deloitte Center for Health Solutions, which researches and develops solutions to some of United Therapeutics Corporation nation's most pressing health care and public health related challenges. He currently serves on the boards of directors of Healthpeak Properties, Inc. and TherapeuticsMD, Inc., each of which is publicly-traded. He resigned as executive chair of the TherapeuticsMD board in March 2024, and was re-appointed as the non-executive chair of the TherapeuticsMD board. He previously served on the boards of various other public companies, including AGA Medical Holdings, Inc., Cancer Genetics Inc., CareView Communications, Inc., Centene Corporation, CNS Response, Inc., C.R. Bard, Inc., Cytori Therapeutics, Inc., Scilex Holding Company, Physicians Realty Trust, SpectraScience, Tyme Technologies, Inc., and X Shares Advisors. Governor Thompson earned his bachelor and juris doctor degrees from the University of Wisconsin–Madison.
- Louis Sullivan
-
Louis Sullivan ,他目前担任Henry Schein公司(2001年以来)和Emergent BioSolutions公司(2005年以来)的董事(均为两个上市公司)。他此前曾任职上市公司的董事会,包括General Motors Company、BioSante Pharmaceuticals公司、Bristol-Myers Squibb Company、 Cigna Corporation、3M Company、Georgia Pacific Corporation。他曾担任Morehouse School of Medicine的创始董事(从1981年到1989年),也曾担任总裁(从1993年到2002年),并于2002年成为荣誉总裁。他也担任South African Blacks公司的创始人之一、医学教育主席,以及美国童子军( the Boy Scouts of America)的全国执行委员会的成员、Little League of America的监事会成员。他曾担任the U.S. Department of Health and Human Services的秘书(从1989年到1993年)。他是一个医生,获得内科血液学专业认证。自2002年以来,他担任United Therapeutics公司的董事。
Louis Sullivan,was the founding President of Morehouse School of Medicine, from 1981 to 1989, served as President again from 1993 to 2002, and has served as President Emeritus since 2002. Dr. Sullivan was also one of the founders and served as Chair of Medical Education for South African Blacks, Inc., a member of the National Executive Council for the Boy Scouts of America, and a member of the Board of Trustees of Little League of America. Dr. Sullivan served as Secretary of the U.S. Department of Health and Human Services from 1989 to 1993. He is a physician certified in internal medicine with a sub-specialty certification in hematology. Dr. Sullivan currently serves on the board of directors of Emergent BioSolutions, Inc. (since 2005), a publicly-traded company. He also serves as Co-Chair of the Henry Schein Cares Foundation. Dr. Sullivan previously served on the boards of directors of a wide range of public companies, including General Motors Company, BioSante Pharmaceuticals, Inc., Bristol Myers Squibb Company, Cigna Corporation, 3M Company, Henry Schein, Inc., Household International (now HSBC), Equifax, and Georgia Pacific Corporation. Dr. Sullivan received his bachelor's degree from Morehouse College, and his medical degree from Boston University. - Louis Sullivan ,他目前担任Henry Schein公司(2001年以来)和Emergent BioSolutions公司(2005年以来)的董事(均为两个上市公司)。他此前曾任职上市公司的董事会,包括General Motors Company、BioSante Pharmaceuticals公司、Bristol-Myers Squibb Company、 Cigna Corporation、3M Company、Georgia Pacific Corporation。他曾担任Morehouse School of Medicine的创始董事(从1981年到1989年),也曾担任总裁(从1993年到2002年),并于2002年成为荣誉总裁。他也担任South African Blacks公司的创始人之一、医学教育主席,以及美国童子军( the Boy Scouts of America)的全国执行委员会的成员、Little League of America的监事会成员。他曾担任the U.S. Department of Health and Human Services的秘书(从1989年到1993年)。他是一个医生,获得内科血液学专业认证。自2002年以来,他担任United Therapeutics公司的董事。
- Louis Sullivan,was the founding President of Morehouse School of Medicine, from 1981 to 1989, served as President again from 1993 to 2002, and has served as President Emeritus since 2002. Dr. Sullivan was also one of the founders and served as Chair of Medical Education for South African Blacks, Inc., a member of the National Executive Council for the Boy Scouts of America, and a member of the Board of Trustees of Little League of America. Dr. Sullivan served as Secretary of the U.S. Department of Health and Human Services from 1989 to 1993. He is a physician certified in internal medicine with a sub-specialty certification in hematology. Dr. Sullivan currently serves on the board of directors of Emergent BioSolutions, Inc. (since 2005), a publicly-traded company. He also serves as Co-Chair of the Henry Schein Cares Foundation. Dr. Sullivan previously served on the boards of directors of a wide range of public companies, including General Motors Company, BioSante Pharmaceuticals, Inc., Bristol Myers Squibb Company, Cigna Corporation, 3M Company, Henry Schein, Inc., Household International (now HSBC), Equifax, and Georgia Pacific Corporation. Dr. Sullivan received his bachelor's degree from Morehouse College, and his medical degree from Boston University.
- Ray Kurzweil
-
Ray Kurzweil,他是一个发明家、企业家和作者,并在人工智能领域创造了几个重要的技术。他获得“the National Medal of Technology”、“the MIT-Lemelson Prize”,以及19个荣誉博士学位和“three U.S. Presidents”。他被选入2002年全国发明家名人堂。1995年以来,他担任Kurzweil Technologies公司(一个技术开发公司)的首席执行官。2013年1月以来,他也曾担任Google公司(全球技术和互联网搜索公司)的工程总监。自2002年以来,他担任United Therapeutics公司的董事。
Ray Kurzweil,is an inventor, entrepreneur, and author, and has created several important technologies in the artificial intelligence field. He has received the National Medal of Technology, the MIT Lemelson Prize, twenty-one honorary doctorates, a Grammy award for his contributions to music technology, and honors from three U.S. Presidents. In 2002, Mr. Kurzweil was inducted into the National Inventors Hall of Fame. Since 1995, Mr. Kurzweil has served as the Chief Executive Officer of Kurzweil Technologies, Inc., a technology development firm. Since January 2013, he has also served as a Director of Engineering and currently serves as Principal Researcher and AI Visionary for Google, a global technology and Internet search company. Mr. Kurzweil previously served on the boards of directors of Inforte Corp. and Medical Manager Corporation, both of which were publicly-traded. Mr. Kurzweil has a B.S. in Computer Science and Literature from the Massachusetts Institute of Technology. - Ray Kurzweil,他是一个发明家、企业家和作者,并在人工智能领域创造了几个重要的技术。他获得“the National Medal of Technology”、“the MIT-Lemelson Prize”,以及19个荣誉博士学位和“three U.S. Presidents”。他被选入2002年全国发明家名人堂。1995年以来,他担任Kurzweil Technologies公司(一个技术开发公司)的首席执行官。2013年1月以来,他也曾担任Google公司(全球技术和互联网搜索公司)的工程总监。自2002年以来,他担任United Therapeutics公司的董事。
- Ray Kurzweil,is an inventor, entrepreneur, and author, and has created several important technologies in the artificial intelligence field. He has received the National Medal of Technology, the MIT Lemelson Prize, twenty-one honorary doctorates, a Grammy award for his contributions to music technology, and honors from three U.S. Presidents. In 2002, Mr. Kurzweil was inducted into the National Inventors Hall of Fame. Since 1995, Mr. Kurzweil has served as the Chief Executive Officer of Kurzweil Technologies, Inc., a technology development firm. Since January 2013, he has also served as a Director of Engineering and currently serves as Principal Researcher and AI Visionary for Google, a global technology and Internet search company. Mr. Kurzweil previously served on the boards of directors of Inforte Corp. and Medical Manager Corporation, both of which were publicly-traded. Mr. Kurzweil has a B.S. in Computer Science and Literature from the Massachusetts Institute of Technology.
- Christopher Causey
-
Christopher Causey,他曾一直担任the Causey Consortium公司(为医疗行业专业服务组织提供业务战略和营销咨询)的负责人(2002年以来)。此前,他曾担任各种各样的医疗和科技公司的高级营销官。从2001年到2002年,他是Definity Health Incorporated公司的首席营销官。他也曾担任Data Sciences International公司(一个私人公司,开发无线生理监控解决方案)的董事会成员(从2008年到2013年)。自2003年以来,他担任United Therapeutics公司的董事。
Christopher Causey,served as the Principal of the Causey Consortium, a professional services organization providing business strategy and marketing counsel to the healthcare industry, from 2002 until his retirement in 2021. Previously, Mr. Causey served as a senior marketing officer for a variety of healthcare companies. From 2001 to 2002, Mr. Causey served as Chief Marketing Officer for Definity Health Incorporated. He was also a member of the board of directors of Data Sciences International, Inc., a private company that develops wireless physiological monitoring solutions, from 2008 to 2013. Mr. Causey currently serves on the Board of Trustees of The College of Wooster. Mr. Causey received his bachelor's degree in psychology from The College of Wooster, and his M.B.A. from The George Washington University. - Christopher Causey,他曾一直担任the Causey Consortium公司(为医疗行业专业服务组织提供业务战略和营销咨询)的负责人(2002年以来)。此前,他曾担任各种各样的医疗和科技公司的高级营销官。从2001年到2002年,他是Definity Health Incorporated公司的首席营销官。他也曾担任Data Sciences International公司(一个私人公司,开发无线生理监控解决方案)的董事会成员(从2008年到2013年)。自2003年以来,他担任United Therapeutics公司的董事。
- Christopher Causey,served as the Principal of the Causey Consortium, a professional services organization providing business strategy and marketing counsel to the healthcare industry, from 2002 until his retirement in 2021. Previously, Mr. Causey served as a senior marketing officer for a variety of healthcare companies. From 2001 to 2002, Mr. Causey served as Chief Marketing Officer for Definity Health Incorporated. He was also a member of the board of directors of Data Sciences International, Inc., a private company that develops wireless physiological monitoring solutions, from 2008 to 2013. Mr. Causey currently serves on the Board of Trustees of The College of Wooster. Mr. Causey received his bachelor's degree in psychology from The College of Wooster, and his M.B.A. from The George Washington University.
- Richard Giltner
-
Richard Giltner,从2009年到2010年退休,他曾担任Lyxor Asset Management公司(the French bank Société Générale的资产管理集团)的投资组合经理。从2006年到2009年,他曾担任Société Générale Asset Management公司(一个国际基金管理公司)的董事总经理,以及其基金的对冲基金集团的欧洲基金主管。从2003年到2006年,他曾担任Société Générale的外汇期权投资银行部门的全球负责人。他也曾担任Société Générale的多种其它管理职务(从1991年到2003年)。2010年退任Société Générale以来,他一直是私人投资者。我们的董事会确定他为一个审计委员会金融专家,基于证券交易委员会的规章制度下定义,并满足纳斯达克上市的金融复杂性要求标准。自2009年以来,他担任United Therapeutics公司的董事。
Richard Giltner,was a portfolio manager at Lyxor Asset Management, an asset management group at the French bank Société Générale. From 2006 until 2009, he served as a managing director of Société Générale Asset Management, an international fund management firm, and head of the European office for its fund of hedge funds group. From 2003 to 2006, Mr. Giltner was the global head of foreign exchange options for the investment banking arm of Société Générale. He also held various other managerial positions within Société Générale from 1991 until 2003. Mr. Giltner has been a private investor since his retirement from Société Générale in 2010. Mr. Giltner received his bachelor's degree from Northwestern University. - Richard Giltner,从2009年到2010年退休,他曾担任Lyxor Asset Management公司(the French bank Société Générale的资产管理集团)的投资组合经理。从2006年到2009年,他曾担任Société Générale Asset Management公司(一个国际基金管理公司)的董事总经理,以及其基金的对冲基金集团的欧洲基金主管。从2003年到2006年,他曾担任Société Générale的外汇期权投资银行部门的全球负责人。他也曾担任Société Générale的多种其它管理职务(从1991年到2003年)。2010年退任Société Générale以来,他一直是私人投资者。我们的董事会确定他为一个审计委员会金融专家,基于证券交易委员会的规章制度下定义,并满足纳斯达克上市的金融复杂性要求标准。自2009年以来,他担任United Therapeutics公司的董事。
- Richard Giltner,was a portfolio manager at Lyxor Asset Management, an asset management group at the French bank Société Générale. From 2006 until 2009, he served as a managing director of Société Générale Asset Management, an international fund management firm, and head of the European office for its fund of hedge funds group. From 2003 to 2006, Mr. Giltner was the global head of foreign exchange options for the investment banking arm of Société Générale. He also held various other managerial positions within Société Générale from 1991 until 2003. Mr. Giltner has been a private investor since his retirement from Société Générale in 2010. Mr. Giltner received his bachelor's degree from Northwestern University.
- Martine A. Rothblatt
-
Martine A. Rothblatt ,她于1996年创立United Therapeutics公司,也曾担任主席兼首席执行官(公司成立以来)。任职United Therapeutics公司之前,她曾创立Sirius XM Satellite Radio公司,并担任董事会主席兼首席执行官。
Martine A. Rothblatt founded United Therapeutics (Nasdaq: UTHR) in 1996 and has served as Chairperson and Chief Executive Officer since its inception. Previoly, she created SiriXM satellite radio (Nasdaq: SIRI), through which she was responsible for enhancing aviation safety by delivery of real time ather information to aircraft in flight and for which, among her many other pioneering efforts in electric aviation, the National Biness Aviation Association (NBAA) selected Dr. Rothblatt in 2021 for its highest honor, the Meritorio Service to Aviation Award. In 2019 she received the inaugural UP Leadership Award for her advances in eVTOL technology, including her creation in 2016 and subsequent piloting to world record distances of the world's first electrically pored full size helicopter. Dr. Rothblatt has over 2000 hs piloting fixed wing and rotorcraft aircraft and served as the first flight engineer for the BETA ALIA. Through United Therapeutics, Dr. Rothblatt oversees hundreds of organ delivery flights per year from transplant donor hospitals to her company's facilities for bioengineering services and then on to transplant recipient hospitals. She also implemented the world's first lung transplant delivered by electric drone. Dr. Rothblatt earned her Doctor of Philosophy in Medical Ethics from the University of London after earning Juris Doctor and Master of Biness Administration degrees from University of California, Los Angeles, which also recently awarded her the University of California, Los Angeles Medal, its highest honor. She is an inventor on ten U.S. patents with additional patents pending. - Martine A. Rothblatt ,她于1996年创立United Therapeutics公司,也曾担任主席兼首席执行官(公司成立以来)。任职United Therapeutics公司之前,她曾创立Sirius XM Satellite Radio公司,并担任董事会主席兼首席执行官。
- Martine A. Rothblatt founded United Therapeutics (Nasdaq: UTHR) in 1996 and has served as Chairperson and Chief Executive Officer since its inception. Previoly, she created SiriXM satellite radio (Nasdaq: SIRI), through which she was responsible for enhancing aviation safety by delivery of real time ather information to aircraft in flight and for which, among her many other pioneering efforts in electric aviation, the National Biness Aviation Association (NBAA) selected Dr. Rothblatt in 2021 for its highest honor, the Meritorio Service to Aviation Award. In 2019 she received the inaugural UP Leadership Award for her advances in eVTOL technology, including her creation in 2016 and subsequent piloting to world record distances of the world's first electrically pored full size helicopter. Dr. Rothblatt has over 2000 hs piloting fixed wing and rotorcraft aircraft and served as the first flight engineer for the BETA ALIA. Through United Therapeutics, Dr. Rothblatt oversees hundreds of organ delivery flights per year from transplant donor hospitals to her company's facilities for bioengineering services and then on to transplant recipient hospitals. She also implemented the world's first lung transplant delivered by electric drone. Dr. Rothblatt earned her Doctor of Philosophy in Medical Ethics from the University of London after earning Juris Doctor and Master of Biness Administration degrees from University of California, Los Angeles, which also recently awarded her the University of California, Los Angeles Medal, its highest honor. She is an inventor on ten U.S. patents with additional patents pending.
- Judy D. Olian
-
Judy D. Olian是加州大学洛杉矶分校的安德森管理学院院长,管理John E. Anderson Chair。她的商业技术中心包括组织设计市场机会,开发一致的人力资源系统和激励,管理高层管理团队。她于2006年担任院长和宾夕法尼亚州立大学工商Smeal学院的管理教授。早些时候,她在马里兰大学和Robert H. Smith 商业学校担任教师和行政职务。她在不同顾问董事会工作,包括北京大学光华商学院,悉尼大学的美国研究中心,催化剂,女性从事商业的全球智库,担任商业新闻勒布奖的主席。她拥有耶路撒冷希伯来大学心理学学士学位,威斯康辛大学麦迪逊劳资关系的硕士和博士学位。
Judy D. Olian,is a Director of Ares Management Corporation. Since 2018 Dr. Olian served as the President of Quinnipiac University. Previously, Dr. Olian served as dean of the UCLA Anderson School of Management and the John E. Anderson Chair in Management from January 2006 to July 2018. Prior to her tenure at UCLA, Dr. Olian served as dean and professor of management at the Smeal College of Business Administration at Pennsylvania State University. Earlier, she served in various faculty and executive roles at the University of Maryland and its Robert H. Smith School of Business. Her business expertise centers on aligning organizations' design with market opportunities, developing strategically aligned human resource systems and incentives, and managing top management teams. In the not-for-profit sector, Dr. Olian serves on the boards of directors of Hartford Healthcare, the Knight Commission for Collegiate Athletics, the Connecticut Conference of Independent Colleges and the New Haven Promise, which works with low income children in the community. Dr. Olian also serves on the boards of directors of United Therapeutics Corporation and Mattel Corporation. She chairs the Division I Metro-Atlantic Athletic Conference and was appointed by the Governor of Connecticut to co-chair AdvanceCT, attracting and retaining businesses into Connecticut. Dr. Olian received her B.S. in Psychology from the Hebrew University, Jerusalem and her M.S. and Ph.D. in Industrial Relations from the University of Wisconsin, Madison. - Judy D. Olian是加州大学洛杉矶分校的安德森管理学院院长,管理John E. Anderson Chair。她的商业技术中心包括组织设计市场机会,开发一致的人力资源系统和激励,管理高层管理团队。她于2006年担任院长和宾夕法尼亚州立大学工商Smeal学院的管理教授。早些时候,她在马里兰大学和Robert H. Smith 商业学校担任教师和行政职务。她在不同顾问董事会工作,包括北京大学光华商学院,悉尼大学的美国研究中心,催化剂,女性从事商业的全球智库,担任商业新闻勒布奖的主席。她拥有耶路撒冷希伯来大学心理学学士学位,威斯康辛大学麦迪逊劳资关系的硕士和博士学位。
- Judy D. Olian,is a Director of Ares Management Corporation. Since 2018 Dr. Olian served as the President of Quinnipiac University. Previously, Dr. Olian served as dean of the UCLA Anderson School of Management and the John E. Anderson Chair in Management from January 2006 to July 2018. Prior to her tenure at UCLA, Dr. Olian served as dean and professor of management at the Smeal College of Business Administration at Pennsylvania State University. Earlier, she served in various faculty and executive roles at the University of Maryland and its Robert H. Smith School of Business. Her business expertise centers on aligning organizations' design with market opportunities, developing strategically aligned human resource systems and incentives, and managing top management teams. In the not-for-profit sector, Dr. Olian serves on the boards of directors of Hartford Healthcare, the Knight Commission for Collegiate Athletics, the Connecticut Conference of Independent Colleges and the New Haven Promise, which works with low income children in the community. Dr. Olian also serves on the boards of directors of United Therapeutics Corporation and Mattel Corporation. She chairs the Division I Metro-Atlantic Athletic Conference and was appointed by the Governor of Connecticut to co-chair AdvanceCT, attracting and retaining businesses into Connecticut. Dr. Olian received her B.S. in Psychology from the Hebrew University, Jerusalem and her M.S. and Ph.D. in Industrial Relations from the University of Wisconsin, Madison.
高管简历
中英对照 |  中文 |  英文- James C. Edgemond
James C. Edgemond,于2013年1月加入United Therapeutics,担任财务主管兼战略财务规划副总裁。Edgemond先生于2015年3月晋升为首席财务官兼财务主管。在加入United Therapeutics之前,他于2008年至2013年1月期间担任Clark Construction Group副总裁、公司财务总监和财务主管。他还曾于1998年至2008年在公司执行董事会公司担任多种职务,2005年至2008年担任财务执行董事。从1990年到1998年,他在KPMG Peat Marwick LLP担任公共会计师,开始了他的职业生涯,在那里他担任过多种职务,包括在离职前担任高级经理。
James C. Edgemond,joined United Therapeutics in January 2013 as Treasurer and Vice President, Strategic Financial Planning. Mr. Edgemond was promoted to Chief Financial Officer and Treasurer in March 2015. Prior to joining United Therapeutics, he was Vice President, Corporate Controller, and Treasurer of Clark Construction Group from 2008 through January 2013. He also served in a variety of roles at The Corporate Executive Board Company from 1998 to 2008, serving as Executive Director, Finance from 2005 to 2008. He began his career as a public accountant at KPMG Peat Marwick LLP, from 1990 through 1998, where he served in a variety of roles, including as a Senior Manager prior to his departure.- James C. Edgemond,于2013年1月加入United Therapeutics,担任财务主管兼战略财务规划副总裁。Edgemond先生于2015年3月晋升为首席财务官兼财务主管。在加入United Therapeutics之前,他于2008年至2013年1月期间担任Clark Construction Group副总裁、公司财务总监和财务主管。他还曾于1998年至2008年在公司执行董事会公司担任多种职务,2005年至2008年担任财务执行董事。从1990年到1998年,他在KPMG Peat Marwick LLP担任公共会计师,开始了他的职业生涯,在那里他担任过多种职务,包括在离职前担任高级经理。
- James C. Edgemond,joined United Therapeutics in January 2013 as Treasurer and Vice President, Strategic Financial Planning. Mr. Edgemond was promoted to Chief Financial Officer and Treasurer in March 2015. Prior to joining United Therapeutics, he was Vice President, Corporate Controller, and Treasurer of Clark Construction Group from 2008 through January 2013. He also served in a variety of roles at The Corporate Executive Board Company from 1998 to 2008, serving as Executive Director, Finance from 2005 to 2008. He began his career as a public accountant at KPMG Peat Marwick LLP, from 1990 through 1998, where he served in a variety of roles, including as a Senior Manager prior to his departure.
- Michael Benkowitz
Michael Benkowitzz于2011年加入United Therapeutics,担任组织发展执行Vice President。在这个职位上,他负责大多数全公司的行政职能,包括人力资源、信息技术、企业房地产和风险管理,也负责我们的许多业务发展努力和监督我们的几个关键合作。他于2016年6月被提拔为总裁兼首席运营官,当时他也负责我们所有的商业和医疗事务活动。
Michael Benkowitz,joined United Therapeutics in 2011 as Executive Vice President, Organizational Development, and was promoted to President and Chief Operating Officer in 2016. He is responsible for all of sales, marketing, market access, patient relations, manufacturing, medical affairs, and corporate compliance activities, most company-wide administrative functions, including human resources and information technology, many of business development efforts, and several of key business alliances and partnerships.- Michael Benkowitzz于2011年加入United Therapeutics,担任组织发展执行Vice President。在这个职位上,他负责大多数全公司的行政职能,包括人力资源、信息技术、企业房地产和风险管理,也负责我们的许多业务发展努力和监督我们的几个关键合作。他于2016年6月被提拔为总裁兼首席运营官,当时他也负责我们所有的商业和医疗事务活动。
- Michael Benkowitz,joined United Therapeutics in 2011 as Executive Vice President, Organizational Development, and was promoted to President and Chief Operating Officer in 2016. He is responsible for all of sales, marketing, market access, patient relations, manufacturing, medical affairs, and corporate compliance activities, most company-wide administrative functions, including human resources and information technology, many of business development efforts, and several of key business alliances and partnerships.
- Paul A. Mahon
Paul A. Mahon, 他是医学博士。他曾担任United Therapeutics公司的法律总顾问和公司秘书(1996年公司成立以来)。他于2001年6月加入United Therapeutics公司,担任全职高级副总裁、法律总顾问和公司秘书。他于2003年11月被任命为高级副总裁、法律总顾问和公司秘书。2001年6月之前,他曾任职United Therapeutics公司(律师事务所,专攻技术和媒体法)(始于1996年公司创立),并担任负责人和管理合伙人。
Paul A. Mahon,has served as General Counsel and Corporate Secretary of United Therapeutics since its inception in 1996. In 2001, Mr. Mahon joined United Therapeutics full-time as Senior Vice President, General Counsel, and Corporate Secretary. In 2003, Mr. Mahon was promoted to Executive Vice President, General Counsel, and Corporate Secretary. Prior to 2001, he served United Therapeutics, beginning with its formation in 1996, in his capacity as principal and managing partner of a law firm specializing in technology and media law.- Paul A. Mahon, 他是医学博士。他曾担任United Therapeutics公司的法律总顾问和公司秘书(1996年公司成立以来)。他于2001年6月加入United Therapeutics公司,担任全职高级副总裁、法律总顾问和公司秘书。他于2003年11月被任命为高级副总裁、法律总顾问和公司秘书。2001年6月之前,他曾任职United Therapeutics公司(律师事务所,专攻技术和媒体法)(始于1996年公司创立),并担任负责人和管理合伙人。
- Paul A. Mahon,has served as General Counsel and Corporate Secretary of United Therapeutics since its inception in 1996. In 2001, Mr. Mahon joined United Therapeutics full-time as Senior Vice President, General Counsel, and Corporate Secretary. In 2003, Mr. Mahon was promoted to Executive Vice President, General Counsel, and Corporate Secretary. Prior to 2001, he served United Therapeutics, beginning with its formation in 1996, in his capacity as principal and managing partner of a law firm specializing in technology and media law.
- Martine A. Rothblatt
Martine A. Rothblatt ,她于1996年创立United Therapeutics公司,也曾担任主席兼首席执行官(公司成立以来)。任职United Therapeutics公司之前,她曾创立Sirius XM Satellite Radio公司,并担任董事会主席兼首席执行官。
Martine A. Rothblatt founded United Therapeutics (Nasdaq: UTHR) in 1996 and has served as Chairperson and Chief Executive Officer since its inception. Previoly, she created SiriXM satellite radio (Nasdaq: SIRI), through which she was responsible for enhancing aviation safety by delivery of real time ather information to aircraft in flight and for which, among her many other pioneering efforts in electric aviation, the National Biness Aviation Association (NBAA) selected Dr. Rothblatt in 2021 for its highest honor, the Meritorio Service to Aviation Award. In 2019 she received the inaugural UP Leadership Award for her advances in eVTOL technology, including her creation in 2016 and subsequent piloting to world record distances of the world's first electrically pored full size helicopter. Dr. Rothblatt has over 2000 hs piloting fixed wing and rotorcraft aircraft and served as the first flight engineer for the BETA ALIA. Through United Therapeutics, Dr. Rothblatt oversees hundreds of organ delivery flights per year from transplant donor hospitals to her company's facilities for bioengineering services and then on to transplant recipient hospitals. She also implemented the world's first lung transplant delivered by electric drone. Dr. Rothblatt earned her Doctor of Philosophy in Medical Ethics from the University of London after earning Juris Doctor and Master of Biness Administration degrees from University of California, Los Angeles, which also recently awarded her the University of California, Los Angeles Medal, its highest honor. She is an inventor on ten U.S. patents with additional patents pending.- Martine A. Rothblatt ,她于1996年创立United Therapeutics公司,也曾担任主席兼首席执行官(公司成立以来)。任职United Therapeutics公司之前,她曾创立Sirius XM Satellite Radio公司,并担任董事会主席兼首席执行官。
- Martine A. Rothblatt founded United Therapeutics (Nasdaq: UTHR) in 1996 and has served as Chairperson and Chief Executive Officer since its inception. Previoly, she created SiriXM satellite radio (Nasdaq: SIRI), through which she was responsible for enhancing aviation safety by delivery of real time ather information to aircraft in flight and for which, among her many other pioneering efforts in electric aviation, the National Biness Aviation Association (NBAA) selected Dr. Rothblatt in 2021 for its highest honor, the Meritorio Service to Aviation Award. In 2019 she received the inaugural UP Leadership Award for her advances in eVTOL technology, including her creation in 2016 and subsequent piloting to world record distances of the world's first electrically pored full size helicopter. Dr. Rothblatt has over 2000 hs piloting fixed wing and rotorcraft aircraft and served as the first flight engineer for the BETA ALIA. Through United Therapeutics, Dr. Rothblatt oversees hundreds of organ delivery flights per year from transplant donor hospitals to her company's facilities for bioengineering services and then on to transplant recipient hospitals. She also implemented the world's first lung transplant delivered by electric drone. Dr. Rothblatt earned her Doctor of Philosophy in Medical Ethics from the University of London after earning Juris Doctor and Master of Biness Administration degrees from University of California, Los Angeles, which also recently awarded her the University of California, Los Angeles Medal, its highest honor. She is an inventor on ten U.S. patents with additional patents pending.